Home / Auditor changes / Benitec Biopharma Inc.
Filed 2026-09-24 路 Form 8-K 路 Accession 0001193125-26-401110 small
Price before filing: $9.83 (2026-09-23 close, split/dividend-adjusted)
Market cap at flag: $448.8M (2026-09-24) 路 Latest: $377.6M (2026-10-16)
| Window | BNTC | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | pending | pending | until 2026-10-24 | |
| 90 days | pending | pending | until 2026-12-23 | |
| 180 days | pending | pending | until 2027-03-23 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"As further outlined below, as a result of such process, the Company appointed Ernst & Young LLP ("EY")."
Quoted from the filing. Source
The company changed its outside auditor (8-K Item 4.01). A dismissal or resignation, especially near an annual report or with reported disagreements, is a warning sign. Changes caused by audit firms merging are usually routine.
Type: dismissed
Disagreements reported: no
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Newsletter delivered by beehiiv. See our privacy policy.